The GLP-1 medication market is seeing significant changes, including FDA approval of oral weight loss drugs and expanded Medicare coverage starting in July 2024. These shifts could make weight loss medications more accessible to patients.
Posts tagged as “insurance and access”
The growing peptide market is creating competition for brand-name GLP-1 drugs as compounding pharmacies offer alternatives to expensive medications. This trend is causing tension between commercial drug companies and compounding pharmacies over patient access to weight loss treatments.
About 80% of employer health plans don't cover GLP-1 medications like Wegovy for weight loss, though some companies are adding coverage hoping it will reduce long-term healthcare costs. Only about 20% of employers currently offer this benefit to their workers.
Amazon is expanding its pharmacy services by adding Novo Nordisk's oral version of Ozempic to its platform. This move positions Amazon to capture more of the growing market for GLP-1 weight loss medications.
A recent poll found that 1 in 8 adults take GLP-1 medications like Ozempic or Wegovy, but 27% still pay out-of-pocket despite having insurance. Understanding your coverage options is crucial since these drugs can cost over $1,000 per month without insurance.
Walmart is expanding its digital health platform to include weight management services and GLP-1 prescribing as the retail giant capitalizes on growing consumer interest in these weight-loss drugs. This move makes these medications more accessible through a major retail chain.
As demand for GLP-1 weight-loss drugs like Ozempic surges, many employers and insurance companies are struggling with the high costs. Some companies that want to offer these benefits to employees are being forced to drop coverage altogether due to expense.
Indian pharmaceutical companies are launching cheaper generic versions of GLP-1 drugs, creating a price war against Novo Nordisk's branded medications like Ozempic and Wegovy. This competition could make these weight-loss treatments more affordable globally.